Mechanisms of resistance to targeted therapies for relapsed or refractory acute myeloid leukemia
- 10 April 2022
- journal article
- review article
- Published by Elsevier in Experimental Hematology
- Vol. 111, 13-24
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (T32CA9357-39)
- National Heart, Lung, and Blood Institute (1R01HL150707, R01HL132392)
This publication has 133 references indexed in Scilit:
- Pim-1 Kinase Phosphorylates and Stabilizes 130 kDa FLT3 and Promotes Aberrant STAT5 Signaling in Acute Myeloid Leukemia with FLT3 Internal Tandem DuplicationPLOS ONE, 2013
- Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutationBlood, 2013
- Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemiaNature, 2012
- IDH mutation impairs histone demethylation and results in a block to cell differentiationNature, 2012
- Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locusBlood, 2011
- The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-HydroxyglutarateCancer Cell, 2010
- FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AMLBlood, 2010
- Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia GenomeNew England Journal of Medicine, 2009
- Mouse models of human AML accurately predict chemotherapy responseGenes & Development, 2009
- Oncogenic Kras Initiates Leukemia in Hematopoietic Stem CellsPLOS Biology, 2009